- Home
- CTRM vs ALLK Comparison
CTRM vs ALLK Comparison
Compare CTRM & ALLK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CTRM
- ALLK
- Stock Information
- Founded
- CTRM 2016
- ALLK 2012
- Country
- CTRM Cyprus
- ALLK United States
- Employees
- CTRM N/A
- ALLK N/A
- Industry
- CTRM Marine Transportation
- ALLK Biotechnology: Pharmaceutical Preparations
- Sector
- CTRM Consumer Discretionary
- ALLK Health Care
- Exchange
- CTRM Nasdaq
- ALLK Nasdaq
- Market Cap
- CTRM 25.0M
- ALLK 23.0M
- IPO Year
- CTRM N/A
- ALLK 2018
- Fundamental
- Price
- CTRM $2.12
- ALLK $0.33
- Analyst Decision
- CTRM
- ALLK Hold
- Analyst Count
- CTRM 0
- ALLK 3
- Target Price
- CTRM N/A
- ALLK $2.00
- AVG Volume (30 Days)
- CTRM 50.1K
- ALLK 2.2M
- Earning Date
- CTRM 05-15-2025
- ALLK 05-08-2025
- Dividend Yield
- CTRM N/A
- ALLK N/A
- EPS Growth
- CTRM N/A
- ALLK N/A
- EPS
- CTRM 2.39
- ALLK N/A
- Revenue
- CTRM $76,443,340.00
- ALLK N/A
- Revenue This Year
- CTRM N/A
- ALLK N/A
- Revenue Next Year
- CTRM N/A
- ALLK N/A
- P/E Ratio
- CTRM $0.88
- ALLK N/A
- Revenue Growth
- CTRM N/A
- ALLK N/A
- 52 Week Low
- CTRM $1.98
- ALLK $0.22
- 52 Week High
- CTRM $5.49
- ALLK $1.56
- Technical
- Relative Strength Index (RSI)
- CTRM 39.47
- ALLK 60.40
- Support Level
- CTRM $1.98
- ALLK $0.31
- Resistance Level
- CTRM $2.22
- ALLK $0.33
- Average True Range (ATR)
- CTRM 0.14
- ALLK 0.00
- MACD
- CTRM 0.01
- ALLK 0.00
- Stochastic Oscillator
- CTRM 45.16
- ALLK 78.50
About CTRM Castor Maritime Inc.
Castor Maritime Inc is a provider of seaborne transportation services for dry bulk cargo, including iron ore, coal, grain, steel products, fertilizers, cement, bauxite, sugar, and scrap metal, among others. The firm operates under two reportable segments namely Dry bulk; Aframax/LR2 tanker; Handysize tanker and Container ship. It generates maximum revenue from the Dry bulk segment.
About ALLK Allakos Inc.
Allakos Inc is a clinical-stage company developing therapeutic antibodies that selectively target immunomodulatory receptors present on the surface of immune effector cells involved in allergic, inflammatory, and proliferative diseases. The company's program, AK006 targets Siglec-6, an inhibitory receptor expressed selectively on mast cells. Binding of AK006 to Siglec-6 is designed to activate the native inhibitory function of the receptor which in turn reduces mast cell activation. Its portfolio consists of antibodies that target receptors, particularly Siglec-6, Siglec-8 and other anti-Siglec antibodies, including some antibodies in preclinical development.